Introduction {#s1}
============

Body mass index (BMI) is a commonly used measure of overall adiposity. However, specific fat depots may confer differential metabolic risk. In particular, central abdominal fat, as measured by waist circumference (WC), may be more strongly associated with the development of metabolic risk factors and cardiovascular disease as compared with BMI [@pgen.1000539-Cassano1]--[@pgen.1000539-Wei1]. Therefore, understanding the pathogenesis of central fat distribution may provide further insight into the relationship between adiposity, cardiometabolic risk, and cardiovascular disease.

Both genetic and environmental factors have been linked to obesity [@pgen.1000539-Rankinen1]. Heritability estimates for BMI and WC range from 30 to 70% in family and twin studies [@pgen.1000539-Lyon1], and multiple quantitative trait loci and candidate genes have been mapped to genes for central adiposity [@pgen.1000539-Rankinen1]. Despite strong evidence for an underlying genetic component, genes for obesity-related traits, particularly central obesity, have been difficult to identify and replicate.

Early genome-wide association studies (GWAS) identified both *FTO* and *MC4R* as genes related to BMI and WC [@pgen.1000539-Chambers1]--[@pgen.1000539-Kring1]. Many new loci have been identified in recent obesity related GWAS studies [@pgen.1000539-Thorleifsson1]--[@pgen.1000539-Meyre1]. However, collectively these variants explain only a small proportion of the variation in adiposity [@pgen.1000539-Chambers1]--[@pgen.1000539-Meyre1]. In addition, no GWAS exist exclusively to identify genes for central fat. Thus, to identify new variants, we carried out a large-scale meta-analysis of GWAS from eight studies to detect variants associated with central body fat distribution.

Methods {#s2}
=======

Study Samples {#s2a}
-------------

Participants for the current analysis were drawn from 8 cohort studies, including the Age, Gene/Environment Susceptibility-Reykjavik Study (AGES- Reykjavik Study), the Atherosclerosis Risk in Communities Study (ARIC), the Cardiovascular Health Study (CHS), the European Special Population Network consortium (EUROSPAN), the Family Heart Study, the Framingham Heart Study, Old Order Amish (OOA), and the Rotterdam Study (RS). These groups comprise the CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium. All participants provided informed consent. Local ethical committees at each institution approved the individual study protocols. [Text S1](#pgen.1000539.s010){ref-type="supplementary-material"} contains details regarding all participating cohorts.

Imputation and Statistical Analysis {#s2b}
-----------------------------------

Common to all analyses were use of the raw WC measures and the assumption of an additive model; study specific details follow. Each study reported an effect allele which was meta-analyzed consistently across all studies. Results are currently presented relative to the minor G allele for the *NRXN3* SNP. In all studies except CHS, MACH (version 1.0.15 in Family Heart, Framingham, EUROSPAN and RS; version 1.0.16 in ARIC, AGES, and OOA) was used to impute all autosomal SNPs on the HapMap, using the publicly available phased haplotypes (release 22, build 36, CEU population) as a reference panel. In CHS, the program BIMBAM was used [@pgen.1000539-Servin1]. Details are provided in [Table S1](#pgen.1000539.s006){ref-type="supplementary-material"} regarding covariates and trait creation.

In ARIC, Framingham, and RS, sex- and either cohort-specific or study center-specific residuals were created after adjustment for age, age-squared, and smoking status. In CHS and Family Heart, linear regression models were used to adjust for age, age-squared, sex, smoking, and study center. In AGES, linear regression models using PLINK v1.04 [@pgen.1000539-Purcell1] were used to adjust for age, age-squared, sex, and smoking. In the OOA the measured genotype mixed effects model was used adjusting for age, age-squared, sex and family structure based on the complete 14-generation pedigree as implemented in ITSNBN [@pgen.1000539-OConnell1]. Framingham employed the linear mixed effect model for continuous traits and the generalized estimating equations for dichotomous traits in R [@pgen.1000539-Team1] to account for family relatedness. In RS, linear regression models were run using MACH2QTL [@pgen.1000539-Li1]. In ARIC and EUROSPAN, all regression models were run using the ProbABEL package from the ABEL set of programs [@pgen.1000539-Aulchenko1] and in EUROSPAN genomic control [@pgen.1000539-Bacanu1] was used to correct standard errors of the effect estimates for relatedness among individuals. The Family Heart Study determined the effect of each SNP using linear mixed effects models to account for the siblings present in the data using SAS.

Principal components calculated using EIGENSTRAT [@pgen.1000539-Price1] were adjusted for in the individual studies when significant in order to account for population substructure.

Meta-Analysis {#s2c}
-------------

A weighted z-score approach was used to conduct meta-analyses with METAL ([www.sph.umich.edu/csg/abecasis/metal/](http://www.sph.umich.edu/csg/abecasis/metal/)). Genomic control correction was applied to each study prior to the full meta-analysis. P-values less than 4.4×10^−7^ were considered genome-wide significant [@pgen.1000539-Gordon1].

In Silico Exchange with the GIANT Consortium {#s2d}
--------------------------------------------

In stage 2 of our study, we conducted an *in silico* exchange of the results of 48 SNPs with the GIANT consortium. To create our list of SNPs to exchange, we first selected the top 34 SNPs from independent loci (defined as SNPs with R^2^\<0.2) from our meta-analysis of WC, excluding SNPs in known loci for adiposity. An additional 14 SNPs of independent loci with a p-value\<1.0×10^−5^ from a secondary list that focused on SNPs for WC with corresponding BMI p-values\>0.01 were also included in an attempt to isolate genes that might be specifically associated with central fat deposition. Our *a priori* threshold for replication was a p-value\<0.001 (0.05/48 SNPs) and/or reaching genome-wide significance in a combined meta-analysis. CHARGE and GIANT results were then meta-analyzed using METAL.

Results {#s3}
=======

[Table 1](#pgen-1000539-t001){ref-type="table"} presents descriptive statistics across the 8 cohorts providing data for the meta-analysis. We had a total sample size of 31,373 individuals of Caucasian descent. Participants were mostly middle-aged with ages ranging from a mean of 45 to 76 years of age.

10.1371/journal.pgen.1000539.t001

###### Descriptive statistics across the eight cohorts.

![](pgen.1000539.t001){#pgen-1000539-t001-1}

  Cohort                      N     Age (years)    \% Women     Current smokers (%)                  Waist Circ (cm)                  BMI (kg/m^2^)
  ------------------------- ------ ------------- ------------- --------------------- ----------------------------------------------- ---------------
  AGES                       3172   76.4 (5.4)    58.0 (1840)       12.7 (402)        100.7 (12.1)[\*](#nt102){ref-type="table-fn"}    27.1 (4.4)
  ARIC                       8097   54.3 (5.7)    52.8 (4276)       25.2 (2036)                        96.2 (13.4)                     27.0 (4.9)
  CHS                        3213   72.3 (5.4)    60.0 (1942)       11.0 (354)                         93.6 (12.6)                     26.4 (4.3)
  Family Heart Study         855    55.6 (11.0)   51.5 (440)        11.9 (101)                         98.6 (13.6)                     27.8 (5.1)
  Framingham Heart Study     7115   45.2 (10.9)   52.7 (3750)       18.8 (1338)                        91.4 (15.0)                     26.0 (5.1)
  Old Order Amish            1134   49.6 (16.8)   48.4 (549)         9.4 (106)                         88.5 (11.4)                     27.0 (4.7)
  Rotterdam Study            5471   69.0 (8.8)    58.6 (3205)       23.0 (1258)                        90.6 (11.2)                     26.3 (3.7)
  EUROSPAN Consortium                                                                                                                
  ERF (Dutch)                1239   48.3 (14.7)   60.1 (744)        43.6 (540)                         87.0 (13.7)                     26.7 (4.7)
  CROATIAN                   784    56.5 (15.3)   58.6 (459)        27.7 (217)                         95.9 (11.8)                     27.3 (4.3)
  MICROS (South Tyrolean)    293    46.3 (15.6)   59.7 (175)        45.3 (125)                         88.5 (13.3)                     25.4 (5.4)

Data provided as mean (standard deviation) for continuous and % (n) for dichotomous data.

**\*:** N = 3167 for WC by tape measure; mean (SD) of WC measured by computed tomography is 125.9(14.0) cm.

[Figure S1](#pgen.1000539.s001){ref-type="supplementary-material"} shows the genome-wide association results for WC in the stage 1 CHARGE-only analysis. The top SNPs for WC were in the *FTO* and *MC4R* genes ([Table S3](#pgen.1000539.s008){ref-type="supplementary-material"}). [Figure S2](#pgen.1000539.s002){ref-type="supplementary-material"} shows the QQ plot for our results excluding SNPs in *FTO* and *MC4R*. For *FTO*, the top SNP was rs1558902 (p = 4.6×10^−19^). For *MC4R*, the top SNP was rs489693 (p = 3.5×10^−7^). The top results excluding SNPs in *FTO* and *MC4R* from our stage 1 meta-analysis are shown in [Table 2](#pgen-1000539-t002){ref-type="table"} along with the stage 2 *in silico* replication results from the GIANT consortium; additional meta-analysis results from CHARGE are presented in [Table S3](#pgen.1000539.s008){ref-type="supplementary-material"}. The lowest p-value on our list, for SNP rs10146997 in the *NRXN3* gene, had a stage 1 meta-analysis p-value of 6.4×10^−7^ and was confirmed in 38,641 participants from the GIANT consortium with a p-value of 0.009 and a combined p-value of 5.3×10^−8^. The *NRXN3* SNP was derived from the list of SNPs associated with WC irrespective of association with BMI. None of the other SNPs that were exchanged were confirmed in GIANT. We do note that while rs10857809 (proxy for rs10857810) in the *FAM40A* gene had a p-value of 0.003 in GIANT, the results were not direction-consistent with CHARGE and therefore did not replicate in the combined analysis.

10.1371/journal.pgen.1000539.t002

###### Top 48 SNPs exchanged with the GIANT Consortium, GIANT p-values, and the combined results.

![](pgen.1000539.t002){#pgen-1000539-t002-2}

  Marker                                             Chromosome   Position    CHARGE pvalue   GIANT pvalue[\*](#nt103){ref-type="table-fn"}   COMBINED pvalue   Nearest Gene[\*\*](#nt104){ref-type="table-fn"}
  ------------------------------------------------- ------------ ----------- --------------- ----------------------------------------------- ----------------- -------------------------------------------------
  rs10146997                                             14       79014915       6.4E-07                          0.009                           5.3E-08                         ***NRXN3***
  rs981113                                               5        75556684       9.8E-07                          0.55                            3.4E-03                         ***SV2C***
  rs7338657                                              13       62299289       1.1E-06                          0.75                            4.4E-04                          *PCDH20*
  rs6714750                                              2        136499639      1.9E-06                          0.48                            2.9E-03                           *DARS*
  rs1555967                                              6        51267954       1.9E-06                          0.07                            3.3E-06                           *PKHD1*
  rs4701252                                              5        21814911       2.5E-06                          0.45                            2.3E-06                         ***CDH12***
  rs4420638                                              19       50114786       3.6E-06                          0.80                            3.8E-04                           *APOC1*
  rs2365642                                              1        199501709      4.1E-06                          0.79                            3.4E-03                           *PKP1*
  rs17008958                                             3        71838178       4.5E-06                          0.18                            5.7E-05                        ***EIF4E3***
  rs7932813                                              11        7664857       4.6E-06                          0.09                            5.0E-06                           *OVCH2*
  rs569406                                               9        77219165       4.7E-06                          0.54                            3.7E-04                           *OSTF1*
  rs6837818                                              4         168112        5.2E-06                          0.81                            1.1E-03                          *ZNF718*
  rs17537900                                             13       42593449       7.3E-06                          0.07                            2.9E-03                          *DNAJC15*
  rs17476669                                             2        50579975       7.9E-06                          0.27                            1.1E-04                         ***NRXN1***
  rs11857639                                             15       71424825       8.0E-06                          0.94                            3.8E-04                         ***HCN4***
  rs3758063                                              8        87754664       1.2E-05                          0.76                            5.4E-03                         ***CNGB3***
  rs804569                                               20       22099652       1.4E-05                          0.29                            1.7E-04                           *FOXA2*
  rs13002346                                             2        133761936      1.6E-05                          0.78                            1.9E-03                         ***NAP5***
  rs7138803                                              12       48533735       1.6E-05                          0.01                            8.0E-07                          *BCDIN3D*
  rs17201502                                             12       48571829       1.7E-05                          0.02                            4.2E-06                         ***FAIM2***
  rs154168                                               5        107078981      1.7E-05                          0.86                            2.0E-03                           *EFNA5*
  rs1324618                                              9        121107783      1.8E-05                          0.62                             0.01                           ***DBC1***
  rs1553754                                              17       43918706       2.0E-05                          0.05                            1.2E-05                           *HOXB1*
  rs12971184                                             18       32134683       2.1E-05                          0.43                             0.03                           ***FHOD3***
  rs253414                                               5        74992273       2.3E-05                          0.47                            8.0E-04                          *C5orf37*
  rs309193                                               19       52317155       2.4E-05                          0.20                            1.8E-04                          *C19orf7*
  rs12457723                                             18       27981438       2.4E-05                          0.14                             0.08                            *RNF138*
  rs8006194                                              14       88980606       2.5E-05                          0.63                             0.01                           ***FOXN3***
  rs10172766                                             2        205587746      3.0E-05                          0.30                             0.01                          ***PARD3B***
  rs11096633                                             2        20067535       3.1E-05                          0.47                            5.2E-04                         ***MATN3***
  rs8049894                                              16       75371885       3.1E-05                          0.67                            1.9E-03                          *CNTNAP4*
  rs12148445                                             15       34703950       3.1E-05                          0.60                             0.01                         ***C15orf41***
  rs9829637                                              3        135638752      3.5E-05                          0.10                            4.9E-05                          *ANAPC13*
  rs7666149                                              4        41017949       3.7E-05                          0.06                            2.1E-05                          *LIMCH1*
  rs13421140                                             2         1753016       4.2E-05                          0.97                            6.1E-03                           *MYT1L*
  rs4238692                                              16       82149934       5.8E-05                          0.14                            1.4E-04                         ***CDH13***
  rs17833967                                             12       13846345       6.0E-05                          0.46                            1.2E-03                        ***GRIN2B***
  rs1532206                                              3        99153367       6.2E-05                          0.89                            9.2E-03                         ***MINA***
  rs6723108                                              2        135196450      6.2E-05                          0.27                            4.4E-04                          *TMEM163*
  rs12704232                                             7        85640166       7.4E-05                          0.61                             0.05                             *GRM3*
  rs12377679                                             9        128437576      8.0E-05                          0.12                            1.1E-04                         ***LMX1B***
  rs1017643                                              6        156835825      9.5E-05                          0.04                            2.6E-05                          *ARID1B*
  rs6485438                                              11       43643194       1.3E-04                          0.09                            9.7E-05                         *HSD17B12*
  rs7116632                                              11       129452949      1.9E-04                          0.74                             0.04                           ***APLP2***
  rs422988                                               1         4718977       2.4E-04                          0.62                            3.5E-03                         ***AJAP1***
  rs5771623                                              22       47415000       2.9E-04                          0.07                             0.28                          ***FAM19A5***
  rs6728666                                              2        216894986      5.3E-04                          0.76                             0.02                          ***MARCH4***
  rs10857810[\*\*\*](#nt105){ref-type="table-fn"}        1        110403320      1.8E-04                          .003                             0.97                          ***FAM40A***

**\*:** GIANT sample size is 38,641.

**\*\*:** Nearest reference is bolded if SNP is within the reference gene.

**\*\*\*:** GIANT SNP is proxy rs10857809 (r^2^ = 0.92).

[Figure 1](#pgen-1000539-g001){ref-type="fig"} presents the genomic region for SNP rs10146997 (intronic) in *NRXN3*. [Table 3](#pgen-1000539-t003){ref-type="table"} shows detailed results of rs10146997 in the *NRXN3* gene by contributing CHARGE study and corresponding results appear in the forest plot in [Figure S3](#pgen.1000539.s003){ref-type="supplementary-material"}; there was no evidence for heterogeneity across the stage 1 studies (p = 0.64). The minor allele (G) frequency (MAF) for rs10146997 in our sample ranged from 0.14 in the OOA to 0.24 in the Croatians; the frequency of the *NRXN3* SNP G allele is 0.275, 1.0, 1.0, and 0.35, in Hapmap CEPH, Han Chinese, Japanese, and Yoruba populations, respectively. This SNP was genotyped in AGES, CHS, Family Heart Study, Rotterdam and all EUROSPAN studies, and imputation scores for the other studies indicated very high quality. Overall, per copy of the G allele, mean WC was increased 0.0498 z-score units (0.65 cm). Beta coefficients (in z-score units) were consistently positive in all samples except the ERF study (β = −0.0098; p = 0.86), which is most likely due to chance. Due to overlap in participants from the Framingham Heart Study and ARIC with those from the Family Heart Study, the CHARGE meta-analysis was re-run for the *NRXN3* SNP without the Family Heart Study; results were essentially unchanged (p = 6.6×10^−7^). Individual study-specific results for rs10146997 from the studies comprising the GIANT consortium can be found in [Table S2](#pgen.1000539.s007){ref-type="supplementary-material"}.

![Regional Association Plot for rs10146997 on chromosome 14 in the stage 1 CHARGE-only analysis.\
The color scheme is red for strong linkage disequilibrium (LD; r^2^≥0.8), orange for moderate LD (r^2^≥0.5 and \<0.8), yellow for weak LD (r^2^≥0.2 and \<0.5) and white for limited or no LD (r^2^\<0.2).](pgen.1000539.g001){#pgen-1000539-g001}

10.1371/journal.pgen.1000539.t003

###### Results per copy of the G allele for rs10146997 by contributing study; beta coefficients expressed as z-scores.

![](pgen.1000539.t003){#pgen-1000539-t003-3}

  Cohort                                       N                     MAF (G)   Imputation Quality Score   Beta Coefficient    SE      p-value
  ------------------------- --------------------------------------- --------- -------------------------- ------------------ ------- ------------
  AGES                                       3170                     0.21            Genotyped                0.058         0.031      0.06
  ARIC                                       8097                     0.22               0.98                  0.032         0.019      0.12
  CHS                                        3213                     0.21            Genotyped                0.103         0.030    0.00048
  Family Heart Study                          855                     0.21            Genotyped                0.003         0.055      0.65
  Framingham Heart Study                     7115                     0.20               1.00                  0.068         0.022     0.0019
  Old Order Amish            1097[\*](#nt107){ref-type="table-fn"}    0.14               0.87                  0.049         0.073      0.33
  Rotterdam Study                            5471                     0.21            Genotyped                0.042         0.024      0.08
  EUROSPAN Consortium                                                                                                               
  ERF (Dutch)                                1241                     0.20            Genotyped                −0.010        0.052      0.86
  Croatia                                     784                     0.24            Genotyped                0.039         0.059      0.52
  MICROS (South Tyrolean)                     293                     0.17            Genotyped                0.057         0.101      0.60
  Meta-analysis results                      31373                    0.21               N/A                   0.0498        0.010   6.4×10^−7^

SE = standard error; MAF = minor allele frequency.

**\*:** Sample size reduced from 1134 because smokers excluded due to the low smoking prevalence.

Within CHARGE we also observed an association of rs10146997 with BMI (p = 7.4×10^−6^). Overall, mean BMI was increased 0.024 z-score units per G allele (0.10 kg/m^2^). When WC was additionally adjusted for BMI, the signal was completely attenuated (0.0065 z-score units per G allele; p = 0.32). The association of rs10146997 with WC was similar in women and men and in older and younger individuals ([Table 4](#pgen-1000539-t004){ref-type="table"}). After excluding smoking from the covariate adjustment list, results were essentially similar. Per copy of the G allele, the odds ratio of having high WC (≥88 cm in women; ≥102 cm in men) was 1.07 (95% CI 1.02--1.11; [Table 4](#pgen-1000539-t004){ref-type="table"}). Similarly, the odds ratio of obesity was 1.13 (95% CI 1.07--1.19).

10.1371/journal.pgen.1000539.t004

###### CHARGE consortium secondary analysis results per copy of the G allele for rs10146997 in 31373 individuals; beta coefficients expressed as z-scores.

![](pgen.1000539.t004){#pgen-1000539-t004-4}

                                           Beta Coefficient    SE      p-value
  --------------------------------------- ------------------ ------- ------------
  Overall                                       0.0498        0.010   6.4×10^−7^
  Overall without adjusting for smoking         0.0460        0.010   5.6×10^−6^
  Sex stratification                                                 
  Women                                         0.0500        0.014   4.7×10^−4^
  Men                                           0.0427        0.013     0.001
  Age stratification                                                 
  \<55 years                                    0.0520        0.017     0.002
  55+ years                                     0.0560        0.013   7.4×10^−6^

                                                       Odds Ratio     95% CI      p-value
  --------------------------------------------------- ------------ ------------ ------------
  WC category[\*](#nt108){ref-type="table-fn"}                                  
  High WC (women ≥88 cm, men ≥102 cm)                     1.07      1.02--1.11     0.003
  BMI categories[\*\*](#nt109){ref-type="table-fn"}                             
  Overweight (BMI 25 to \<30)                             1.03      0.98--1.07     0.250
  Obese (BMI≥30)                                          1.13      1.07--1.19   3.2×10^−5^

**\*:** Referent = normal WC category (women \<88 cm; men \<102 cm).

**\*\*:** Referent = normal weight category (BMI 18.5-\<25 kg/m2).

We calculated a risk score of *FTO* (rs9939609), *MC4R* (rs17782313), and *NRXN3* with possible scores ranging from 0--6 risk alleles ([Figure 2](#pgen-1000539-g002){ref-type="fig"}). Across this range, mean WC increased from 92.4 cm among those with 0 risk alleles, to 95.7 cm among those with 4 or more risk alleles. To put our findings in perspective, per copy of the effect allele, the *NRXN3* SNP resulted in a WC difference of 0.65 cm; *FTO* 0.73 cm, and *MC4R* 0.37 cm.

![Mean waist circumference by number of risk alleles for *FTO*, *MC4R*, and *NRXN3*.\
Bars represent standard errors. The panel on the left represents the distribution of risk alleles in the overall sample.](pgen.1000539.g002){#pgen-1000539-g002}

CHARGE consortium meta-analysis results for BMI can be found in [Table S4](#pgen.1000539.s009){ref-type="supplementary-material"}; Manhattan and QQ plots for BMI can be found in [Figure S4](#pgen.1000539.s004){ref-type="supplementary-material"} and [Figure S5](#pgen.1000539.s005){ref-type="supplementary-material"}, respectively.

Discussion {#s4}
==========

In a discovery sample of more than 30,000 individuals from several cohort studies, we identified a novel locus in the *NRXN3* gene associated with WC. In combination with data from the GIANT consortium, the p-value for this finding exceeded our pre-defined threshold for genome-wide statistical significance. This SNP was also significantly associated with BMI and obesity. This gene has previously been associated with addiction and reward behavior, and is a compelling biologic candidate for obesity. We also confirmed the significant associations with *FTO* and *MC4R* that have previously been reported.

Although our genome-wide scan was performed for WC, the *NRXN3* SNP was also significantly associated with BMI. In secondary analyses, the signal for WC was attenuated after additionally adjusting for BMI, suggesting that this locus is most likely involved in overall adiposity and not specific to central fat deposition. Similar observations have been made for *FTO* [@pgen.1000539-Kring1] and *MC4R* [@pgen.1000539-Chambers1], highlighting the inter-dependence between different measures of adiposity and the importance of performing GWAS on multiple adiposity-related traits.

The small magnitude of the effect size of the *NRXN3* variant on WC is consistent with what has previously been reported for *FTO* and *MC4R*. These findings highlight the need for large sample sizes in order to facilitate continued gene discovery for obesity-related traits. In particular, genes that emerge for waist circumference will most likely be genes for overall adiposity because of the strong correlation between the two measurements [@pgen.1000539-Gordon1]. More specific measures of visceral abdominal fat depots may make it possible to isolate genes involved in regional body composition.

*NRXN3* is part of a family of central nervous adhesion molecules and is highly expressed in the central nervous system. Prior studies of *NRNX3* point towards an important role in alcohol dependence, cocaine addiction, and illegal substance abuse [@pgen.1000539-Lachman1]--[@pgen.1000539-Rapaka1]. In addition, opioid dependence has been linked to the chromosome 14q region [@pgen.1000539-Lachman1]. In mice, NRXN3 beta expression was observed in the globus pallidus when exposed to cocaine [@pgen.1000539-Kelai1]. Many of the neuronal pathways in these sub-cortical regions of the brain in which NRXN3 is expressed are involved with learning and reward training [@pgen.1000539-Clay1].

Obesity and addiction may share common neurologic underpinnings [@pgen.1000539-Rapaka1]. Other well-replicated obesity loci, including *MC4R*, have also been shown to be associated with centrally-mediated phenomena including binge eating behavior [@pgen.1000539-Thorleifsson1],[@pgen.1000539-Willer1],[@pgen.1000539-Branson1]. Studies in mice indicate that *FTO* expression is particularly pronounced in regions of the brain known to regulate energy balance [@pgen.1000539-Gerken1], and recent data suggest that variants in the *FTO* gene may regulate food intake and selection [@pgen.1000539-Cecil1].

Additional research is needed to understand the association of rs10146997 with the *NRXN3* gene and to identify a causal variant. Since there are no other genes within a distance of more than several hundred kilobases of this SNP, it is unlikely that a different gene accounts for this finding. A search of publically available databases [@pgen.1000539-Myers1]--[@pgen.1000539-Schadt1] did not identify an association between SNPs in *NRXN3* and gene expression.

A relationship between WC and causal variants in the *NRXN3* gene may have clinical implications. Obesity is a multifactorial trait that results from a complex interaction between genes and environment. The identification of an association between obesity and variants in a gene that has been associated with substance abuse suggests that further exploration of the role of this gene in vulnerability to addiction to food substances should be undertaken.

The strengths of this work include the large discovery sample size. The effect size was small, and achieving conventional levels of genome-wide significance required combining data from more than 70,000 participants in two large consortia. Although the confirmation with the GIANT consortium is promising, the joint p-value based on more than 70,000 participants achieved only borderline genome-wide significance. Our findings warrant the need for further replication in other ethnic groups.

We identified a SNP at a novel locus in the *NRXN3* gene associated with WC. This gene has previously been implicated in addiction and reward behavior, lending further support to the concept that obesity, in part, is a centrally-mediated disorder.
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